GREAT PROFITS ON OUR SHORT ON MS WALKING DRUG COMPANY ACORDA, STOCK CRUSHED ON PATENT RULING $ACOR

acor-blog

This post was just published on ZYX Short Sell Change Alert.

ACOR is short from $48.73.  The stock was halted at $20.33, down $6.44.  The stock was being crushed before the halt as patents on Ampyra are invalidated.  ACOR came to fame on Ampyra, a drug that marginally helps MS patients’ walking.

We have a long history with shorting this stock.

Before the halt the stock had fallen into the target zone of $14 to $21.   20% of the full core position size is being held.

What To Do Now

If the stock opens lower or right around the close before the halt, depending upon your account size, consider taking profits on one-quarter to one-half of your position.

For those not in the stock, consider waiting for a signal on the Real Time Feed.

Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007.  Please click here and scroll down to see the table of all trades.  These trades have been scrutinized in real-time by thousands of subscribers across the globe.  This provides easy verification of performance for newcomers to this site.  Only those trades are included in the performance where the entry post was made available to subscribers to The Arora Report Market Blog.  When the entry post is made available only to the paying subscribers and not posted in real-time on The Arora Report Market Blog, the resulting performance of the trade is not credited in the performance table.  There are very nice gains on this trade but since the entry trade was not posted here in real-time, handsome profits on this trade will not be added to the performance of The Arora Report Market Blog shown on the table.

You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

Check out our enviable performance in both bull and bear markets.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER

Related Posts

ACORDA THERAPEUTICS (ACOR): TIME TO TAKE PROFITS

It is time to take profits on Acorda Therapeutics (ACOR).   Consider  taking profits on the entire position of Acorda ...

ACORDA THERAPEUTICS (ACOR) AND BIOGEN (BIIB) RUMOR MONGERS OUT IN FORCE

Acorda Therapeutics (ACOR)  rumor spreaders are out in force. They are misleading the uninformed investors about a statement Biogen ...

TAKING PARTIAL PROFITS ON ACORDA THERAPEUTICS (ACOR)

Subscribers to ZYX  Short Sell Change Alert took partial profits on Acorda  Therapeutics (ACOR)at $30.20 on Friday. We are holding ...

ACORDA THERAPEUTICS (ACOR) UP MOVE IS AN OPPORTUNITY

Acorda Therapeutics (ACOR) is up due to the positive opinion on Marketing Authorization Application for its MS drug Ampyra in Europe.  This ...

PROTECTING PROFITS ON ACOR

We are lowering the stop on ACOR to $22.39 to protect profits.

NOW WE ARE SHORT ON ACOR

As per the prior  post, now we are short on ACOR   from $30.98.

WE HAVE BEEN PROVEN RIGHT ON AMPYRA FROM ACORDA THERAPEUTICS

Today Acorda Therapeutics (ACOR) reported earnings. Acorda stock has risen on hopes for blockbuster sales of its MS walking drug ...

EXITING ACOR WITH PROFIT RIGHT HERE AT $32.61.

Our negative thesis on Acordia Therapeutics (ACOR) has not changed.  However we are positive on the group, therefore we will ...

ADDING TO $ACOR (ACORDA THERAPEUTICS) SHORT SALE POSITION HERE AT $38.15

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE ...

AS PER PRIOR POST, ADDING TO $ACOR (ACORDIA) SHORT AT $33.37

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE ...

UPDATE ON OPEN INDIVIDUAL STOCK POSITIONS

We are exiting $BCRX and $AVAV; please see separate posts for the reasons.We are short on $ACOR with average price ...

WOW! FDA AGREES WITH OUR LONGSTANDING ASSESSMENT OF FAMPRIDINE-SR , SHORT SELL $ACOR (ACORDIA) PER OUR PRIOR POST

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE ...

ACOR (ACORDIA) FAMPRIDINE IS NOT A VERY GOOD DRUG EVEN IF IT WORKS AS ADVERTISED

The FDA Peripheral and Central Nervous System Drugs Advisory Committee meets today to review ACOR's Fampridine-SR for improvement of walking ...

Follow

Get every new post delivered to your Inbox

Join other followers